IRF3 (2C4) Monoclonal Antibody

$Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HeLa cells labeled with IRF3 (2C4) Monoclonal Antibody (bsm-51312M) at 1\/25 dilution, followed by secondary antibody (green), cytoplasmic actin staining (red), and nuclear counter stain with DAPI (blue).$

Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HeLa cells labeled with IRF3 (2C4) Monoclonal Antibody (bsm-51312M) at 1\/25 dilution, followed by secondary antibody (green), cytoplasmic actin staining (red), and nuclear counter stain with DAPI (blue).

$Jurkat cells probed with using IRF3 (2C4) Monoclonal Antibody bsm-51312M at 1:25 for 60 minutes at 37\u00baC followed by secondary antibody at 1:400 (green) compared to an isotype control of mouse IgG (blue).$

Jurkat cells probed with using IRF3 (2C4) Monoclonal Antibody bsm-51312M at 1:25 for 60 minutes at 37\u00baC followed by secondary antibody at 1:400 (green) compared to an isotype control of mouse IgG (blue).

$Lane 1: COS-7; Lane 2: Daudi; Lane 3: HepG2; Lane 4: HT-29; Lane 5: Jurkat; Lane 6: MCF-7; probed with IRF3 (2C4) Polyclonal Antibody, unconjugated (bsm-51312M) at 1:2000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.$

Lane 1: COS-7; Lane 2: Daudi; Lane 3: HepG2; Lane 4: HT-29; Lane 5: Jurkat; Lane 6: MCF-7; probed with IRF3 (2C4) Polyclonal Antibody, unconjugated (bsm-51312M) at 1:2000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.

$Paraformaldehyde-fixed, paraffin embedded human kidney tissue; Blocked with 3% BSA for 30min at RT; Antibody incubation with IRF3 (2C4) Monoclonal Antibody, Unconjugated (bsm-51312M) at 1:25 for 1hr at 37\u00b0C, followed by a conjugated secondary antibody and DAB staining.$

Paraformaldehyde-fixed, paraffin embedded human kidney tissue; Blocked with 3% BSA for 30min at RT; Antibody incubation with IRF3 (2C4) Monoclonal Antibody, Unconjugated (bsm-51312M) at 1:25 for 1hr at 37\u00b0C, followed by a conjugated secondary antibody and DAB staining.

Applications

WB
FCM
IHC-P
IF(ICC)
IF

Predicted Reactivity

Human

Overview
Catalog #	bsm-51312M
Product Name	IRF3 (2C4) Monoclonal Antibody
Applications	WB FCM IHC-P IF(ICC) IF
Predicted Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Mouse
Source	This IRF3 antibody is generated from a mouse immunized with a recombinant protein.
Clonality	Monoclonal
Clone #	2C4
Isotype	IgG1
Concentration	0.5ug/ul
Purification	Purified by Protein G.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	3661
Swiss Prot	Q14653
Synonyms	IIAE7; Interferon regulatory factor 3; IRF-3; IRF3
Background	Key transcriptional regulator of type I interferon (IFN)-dependent immune responses which plays a critical role in the innate immune response against DNA and RNA viruses. Regulates the transcription of type I IFN genes (IFN-alpha and IFN-beta) and IFN-stimulated genes (ISG) by binding to an interferon-stimulated response element (ISRE) in their promoters. Acts as a more potent activator of the IFN-beta (IFNB) gene than the IFN-alpha (IFNA) gene and plays a critical role in both the early and late phases of the IFNA/B gene induction. Found in an inactive form in the cytoplasm of uninfected cells and following viral infection, double-stranded RNA (dsRNA), or toll-like receptor (TLR) signaling, is phosphorylated by IKBKE and TBK1 kinases. This induces a conformational change, leading to its dimerization and nuclear localization and association with CREB binding protein (CREBBP) to form dsRNA-activated factor 1 (DRAF1), a complex which activates the transcription of the type I IFN and ISG genes. Can activate distinct gene expression programs in macrophages and can induce significant apoptosis in primary macrophages.
Application Dilution
WB	1:300-5000
FCM	1:20-100
IHC-P	1:200-400
IF(ICC)	1:50-200
IF